Japan Cell and Gene Therapy Market Trends, Share, Size, Demand, Revenue and Future Outlook
Japan Cell and Gene Therapy Market Growth, Size, Trends Analysis- By Therapy Type, By Indication, By Delivery Mode, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Dec-2024 | Report ID: HLCA2495 | Pages: 1 - 107 | Formats*: |
| Category : Healthcare | |||
Japan Cell and Gene Therapy Market Introduction and Overview
According to SPER Market Research, the Japan Cell and Gene Therapy Market is estimated to reach USD 9744.68 million by 2033 with a CAGR of 12.71%.
The report includes an in-depth analysis of the Japan Cell and Gene Therapy Market, including market size and trends, product mix, applications, and supplier analysis. Gene therapy is a new medical method that aims to address and potentially eliminate diseases by modifying genes within an individual's cells. This advanced approach involves the introduction, deletion, or modification of genetic information in a patient's cells, with the primary goal of correcting genetic defects that cause various diseases. Therapeutic deoxyribonucleic acid (DNA), a delivery vector that permits DNA transfer into cells, and advanced gene-editing tools, such as CRISPR, are required for gene therapy to function. It has a wide range of applications, including cancer treatment, viral infection management, cardiovascular disease (CVD), neurological disorders, autoimmune diseases, age-related illnesses, specific types of blindness, and genetic disorders such as hemophilia, cystic fibrosis, and sickle cell disease.
- Johnson & Johnson announced in April 2024 that the United States Food and Drug Administration (FDA) has approved CARVYKTI (ciltacabtagene autoleucel), a CAR T-cell treatment that targets the B-cell maturation antigen (BCMA).
- Bristol Myers Squibb (BMS) and 2seventy Bio, Inc. announced in April 2024 that the United States Food and Drug Administration (FDA) had authorized ABECMA (idecabtagene vicleucel) for adult patients with relapsed or refractory multiple myeloma who had received two or more prior lines of therapy.
Market Opportunities and Challenges
Opportunities- The market for cell and gene therapy in Japan is quickly becoming one of the most vibrant and promising areas of the nation's healthcare system. The need for novel treatments that can provide long-term solutions is increased due to an aging population and an increase in the prevalence of chronic illnesses. Because of their potential to treat unmet medical needs, cell and gene therapy have attracted a lot of interest and investment in Japan. Using these state-of-the-art technologies, Japanese researchers and biopharmaceutical companies have been actively working on generating innovative medicines. Japan is a desirable market for both domestic and foreign companies since regulatory bodies there have also taken action to support the clinical development and commercialization of cell and gene treatments.
Challenges:
High Manufacturing prices - Cell and gene therapy manufacturing entails intricate and resource-intensive processes, which raises production prices. The broad use and accessibility of these treatments are hampered by their exorbitant costs.
Regulatory and Reimbursement Difficulties - Cell and gene therapies face a changing and sometimes complicated regulatory environment. The commercialization and accessibility of these treatments may be impacted by the time and resource commitment required to navigate reimbursement procedures and obtain regulatory clearances.
Market Competitive Landscape
There are many businesses operating in the fiercely competitive cell and gene therapy manufacturing market. Important market participants include: Bristol-Myers Squibb Company, 2seventy bio, Inc, Novartis AG, Gilead Sciences Inc (Kite Pharma), Spark Therapeutics, Inc, Nipro Corporation, JCR Pharmaceuticals Co., Ltd, Aurion Biotech, Johnson & Johnson Services, Inc, Terumo BCT.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Therapy Type, By Indication, By Delivery Mode, By End User |
| Regions covered | Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, Shikoku Region. |
| Companies Covered | Bristol-Myers Squibb Company, 2seventy bio, Inc, Novartis AG, Gilead Sciences Inc (Kite Pharma), Spark Therapeutics, Inc, Nipro Corporation, JCR Pharmaceuticals Co., Ltd, Aurion Biotech, Johnson & Johnson Services, Inc, Terumo BCT. |
By Therapy Type Insights:
It is anticipated that the cell therapy market would expand significantly over the course of the projected period. Cell therapy is a state-of-the-art therapeutic approach in which patients get living cells to cure a variety of illnesses. Both allogeneic and autologous cells are used in this therapeutic strategy. Because of its potential for individualized medicine, the cell therapy business is expanding significantly. To meet the growing need for innovative therapies for chronic illnesses, businesses are creating cell therapy products using a variety of cell lines, including stem cells.
COVID-19 Impact on Japan Cell and Gene Therapy Market
The COVID-19 pandemic has had a substantial influence on the cell and gene therapy manufacturing sector.
Accelerated Research and Development - The pandemic has spurred research and development of cell and gene treatments, which have the potential to treat COVID-19 and related problems.
Regulatory Adjustments - Regulatory bodies have facilitated faster development and production of COVID-19-related cell and gene therapies by offering flexibilities and accelerated approval pathways.
Key Target Audience:
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutions
- Healthcare Providers and Hospitals
- Regenerative Medicine Companies
- Contract Research and Manufacturing Organizations (CROs and CMOs)
- Government and Regulatory Bodies
- Investors and Venture Capitalists
- Patient Advocacy Groups
- Specialized Clinics
- Medical Device Manufacturers
Our in-depth analysis of the Japan Cell and Gene Therapy Market includes the following segments:
| By Therapy Type: | |
| By Indication: | |
| By Delivery Mode: | |
| By End User: |
Key Topics Covered in the Report:
- Japan Cell and Gene Therapy Market Size (FY’2024-FY’2033)
- Overview of Japan Cell and Gene Therapy Market
- Segmentation of Japan Cell and Gene Therapy Market by Therapy Type (Cell Therapy, Gene Therapy)
- Segmentation of Japan Cell and Gene Therapy Market by Indication (Cardiovascular Disease, Oncology Disorder, Genetic Disorder, Infectious Disease, Neurological Disorder, and Others)
- Segmentation of Japan Cell and Gene Therapy Market by Delivery Mode (In-Vivo, Ex-Vivo)
- Segmentation of Japan Cell and Gene Therapy Market by End User (Hospitals, Cancer Care Centers, Pharmaceutical and Biotechnology Companies, and Others)
- Statistical Snap of Japan Cell and Gene Therapy Market
- Expansion Analysis of Japan Cell and Gene Therapy Market
- Problems and Obstacles in Japan Cell and Gene Therapy Market
- Competitive Landscape Japan Cell and Gene Therapy Market
- Impact of COVID-19 and Demonetization Japan Cell and Gene Therapy Market
- Details on Current Investment in Japan Cell and Gene Therapy Market
- Competitive Analysis of Japan Cell and Gene Therapy Market
- Prominent Players in the Japan Cell and Gene Therapy Market
- SWOT Analysis of Japan Cell and Gene Therapy Market
- Japan Cell and Gene Therapy Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Japan Cell and Gene Therapy Market.
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Japan Cell and Gene Therapy Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Japan Cell and Gene Therapy Market
7. Japan Cell and Gene Therapy Market, By Therapy Type (USD Million) 2020-2033
7.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Therapy Type, 2020-20267.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Therapy Type, 2027-20337.3. Cell Therapy7.3.1. Stem Cell7.3.2. Non-Stem Cell7.4. Gene Therapy
8. Japan Cell and Gene Therapy Market, By Indication (USD Million) 2020-2033
8.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Indication, 2020-20268.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Indication, 2027-20338.3. Cardiovascular Disease8.4. Oncology Disorder8.5. Genetic Disorder8.6. Infectious Disease8.7. Neurological Disorder8.8. Others
9. Japan Cell and Gene Therapy Market, By Delivery Mode (USD Million) 2020-2033
9.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Delivery Mode, 2020-20269.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Delivery Mode, 2027-20339.3. In-Vivo9.4. Ex-Vivo
10. Japan Cell and Gene Therapy Market, By End User (USD Million) 2020-2033
10.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By End User, 2020-202610.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By End User, 2027-203310.3. Hospitals10.4. Cancer Care Centers10.5. Pharmaceutical and Biotechnology Companies10.6. Others
11. Japan Cell and Gene Therapy Market Forecast, 2020-2033 (USD Million)
11.1. Japan Cell and Gene Therapy Market Size and Market Share
12. Japan Cell and Gene Therapy Market, By Region, 2020-2033 (USD Million)
12.1. Japan Cell and Gene Therapy Market Size and Market Share By Region (2020-2026)12.2. Japan Cell and Gene Therapy Market Size and Market Share By Region (2027-2033)12.3. Kanto Region12.4. Kansai/Kinki Region12.5. Central/ Chubu Region12.6. Kyushu-Okinawa Region12.7. Tohoku Region12.8. Chugoku Region12.9. Hokkaido Region12.10. Shikoku Region
13. Company Profile
13.1. Bristol-Myers Squibb Company13.1.1. Company details13.1.2. Financial outlook13.1.3. Product summary13.1.4. Recent developments13.2. 2seventy bio, Inc13.2.1. Company details13.2.2. Financial outlook13.2.3. Product summary13.2.4. Recent developments13.3. Novartis AG13.3.1. Company details13.3.2. Financial outlook13.3.3. Product summary13.3.4. Recent developments13.4. Gilead Sciences Inc13.4.1. Company details13.4.2. Financial outlook13.4.3. Product summary13.4.4. Recent developments13.5. Spark Therapeutics, Inc13.5.1. Company details13.5.2. Financial outlook13.5.3. Product summary13.5.4. Recent developments13.6. Nipro Corporation13.6.1. Company details13.6.2. Financial outlook13.6.3. Product summary13.6.4. Recent developments13.7. JCR Pharmaceuticals Co., Ltd13.7.1. Company details13.7.2. Financial outlook13.7.3. Product summary13.7.4. Recent developments13.8. Aurion Biotech13.8.1. Company details13.8.2. Financial outlook13.8.3. Product summary13.8.4. Recent developments13.9. Johnson & Johnson Services, Inc13.9.1. Company details13.9.2. Financial outlook13.9.3. Product summary13.9.4. Recent developments13.10. Terumo BCT13.10.1. Company details13.10.2. Financial outlook13.10.3. Product summary13.10.4. Recent developments13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Japan Cell and Gene Therapy Market is projected to reach USD 9744.68 million by 2033, growing at a CAGR of 12.71% during the forecast period.
Japan Cell and Gene Therapy Market grew in Market size from 2024. The Market is expected to reach USD 9744.68 million by 2033, at a CAGR of 12.71% during the forecast period.
Japan Cell and Gene Therapy Market CAGR of 12.71% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Japan Cell and Gene Therapy Market size is USD 9744.68 million from 2024 to 2033.
Japan Cell and Gene Therapy Market is covered By Therapy Type, By Indication, By Delivery Mode, By End User
The Asia Pacific is anticipated to have the highest Market share in the Japan Cell and Gene Therapy Market.
The Key players in the Market include Companies Covered Bristol-Myers Squibb Company, 2seventy bio, Inc, Novartis AG, Gilead Sciences Inc (Kite Pharma), Spark Therapeutics, Inc, Nipro Corporation, JCR Pharmaceuticals Co., Ltd, Aurion Biotech, Johnson & Johnson Services, Inc, Terumo BCT.
The high cost of advanced diabetes drugs and the financial burden of treating diabetes remain major obstacles to market growth, despite the fact that numerous drugs have been approved for the condition and that governments and industry players are launching numerous initiatives.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
